Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: Mol Cancer Ther. 2013 Jan 31;12(2):220–229. doi: 10.1158/1535-7163.MCT-12-0620

Figure 1.

Figure 1

Distribution of all primary EGFR mutations identified in the current study. Although, based on our analysis, insertions in exon 20 corresponded to 9% of all EGFR mutated samples, we estimate that the true incidence may be even higher, closer to 11%, factoring in the expected positive cases which would have been detected if the entire negative group had been tested. Figure includes 5 cases with double mutations as follows *2 cases with double mutations G719A/S768I and G719S/E709A, **2 cases with concurrent T790M at baseline, *** 1 case with concurrent T790M at baseline.